share_log

Chardan Capital Initiates Coverage On Omega Therapeutics With Buy Rating, Announces Price Target of $12

Benzinga Real-time News ·  Sep 23, 2022 05:48

Chardan Capital analyst Keay Nakae initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Buy rating and announces Price Target of $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment